Home > Resources > Whitepapers > Harnessing innovative technologies

Harnessing innovative technologies

Introduction: The rise of the super-bug in today’s world, the biodiversity of vital ecosystems is threatened by factors, such as overpopulation, deforestation, mass migrations, war, famine, depletion of natural resources and animal-human interactions.1 These elements are increasing the sharing of microbial agents and antimicrobial resistance, which can facilitate the emergence of new or previously recognized disease agents. The damaging effects of antimicrobial resistance are increasingly being seen around the world. This issue recently hit the headlines with an industry declaration on combating antimicrobial resistance at the World Economic Forum in Davos, Switzerland.

I'm For Real

Enter your details once to access all our information and resources

 

Spotlight

Amil

Amil is an iconic healthcare company in Brazil and is part of the UnitedHealth Group, the largest and most diversified healthcare group in the world, offering benefits and services in more than 130 countries to about 140 million people. We combine expertise and leadership to coordinate all agents of the health system, creating sustainable relationships to meet and meet the needs of each individual and allow them to live their best, with the right care, at the right time and in the right place.

OTHER WHITEPAPERS
news image

MOLECULAR GLUES LANDSCAPE IN DRUG DISCOVERY

whitePaper | June 21, 2022

nduced-proximity targeted protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged during the last decade.

Read More
news image

New Active Substances Launched During 2021

whitePaper | June 27, 2022

Following on from our review of trends in the current pharmaceutical R&D pipeline this supplement takes a look at the industry’s success stories of 2021

Read More
news image

How Specialty Pharmacy Can Drive Better Outcomes in Cystic Fibrosis

whitePaper | June 28, 2022

CF is a rare, autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene that encodes the CFTR protein, an anion channel normally present in the epithelial membrane.1,2

Read More
news image

3 Pillars to Support a Winning Product Launch

whitePaper | January 18, 2023

The lifetime success of a pharmaceutical product is determined within the first few months following a product launch. Two-thirds of all product launches underperform and the majority of launches fail due to lack.

Read More
news image

Patients Diagnosed with Post-COVID Conditions

whitePaper | May 18, 2022

Post-COVID conditions, also known by such terms as long COVID and post-acute sequelae of COVID-19, have become an issue of growing national concern.

Read More
news image

Manual No More: Automating the Scientific Data Lifecycle

whitePaper | May 23, 2022

The world’s scientific data today is a morass. 50-80% of research scientist and data scientist time is spent wrestling with data before they can focus on highervalue AI/ML and advanced analysis to help bring new life-saving therapeutics to market.

Read More

MOLECULAR GLUES LANDSCAPE IN DRUG DISCOVERY

whitePaper | June 21, 2022

nduced-proximity targeted protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged during the last decade.

Read More

New Active Substances Launched During 2021

whitePaper | June 27, 2022

Following on from our review of trends in the current pharmaceutical R&D pipeline this supplement takes a look at the industry’s success stories of 2021

Read More

How Specialty Pharmacy Can Drive Better Outcomes in Cystic Fibrosis

whitePaper | June 28, 2022

CF is a rare, autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene that encodes the CFTR protein, an anion channel normally present in the epithelial membrane.1,2

Read More

3 Pillars to Support a Winning Product Launch

whitePaper | January 18, 2023

The lifetime success of a pharmaceutical product is determined within the first few months following a product launch. Two-thirds of all product launches underperform and the majority of launches fail due to lack.

Read More

Patients Diagnosed with Post-COVID Conditions

whitePaper | May 18, 2022

Post-COVID conditions, also known by such terms as long COVID and post-acute sequelae of COVID-19, have become an issue of growing national concern.

Read More

Manual No More: Automating the Scientific Data Lifecycle

whitePaper | May 23, 2022

The world’s scientific data today is a morass. 50-80%
of research scientist and data scientist time is spent
wrestling with data before they can focus on highervalue AI/ML and advanced analysis to help bring
new life-saving therapeutics to market.

Read More
More Whitepapers

Spotlight

Amil

Amil is an iconic healthcare company in Brazil and is part of the UnitedHealth Group, the largest and most diversified healthcare group in the world, offering benefits and services in more than 130 countries to about 140 million people. We combine expertise and leadership to coordinate all agents of the health system, creating sustainable relationships to meet and meet the needs of each individual and allow them to live their best, with the right care, at the right time and in the right place.

Events

Pharma 2024

Conference

Pharma 2024

Conference